ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL

ADC Therapeutics Ltd

ADC Therapeutics Ltd

ADCT

0.00
  • ADC Therapeutics completed enrollment in the LOTIS-7 Phase 1b trial testing ZYNLONTA with Roche’s COLUMVI in relapsed or refractory DLBCL.
  • Early study results have already been presented, showing strong tumor shrinkage rates with side effects viewed as manageable.
  • Full results will be presented in Q4 2026, with publication targeted by end-2026.
  • The company plans to evaluate regulatory and compendia options, signaling a potential push toward broader adoption if later data hold up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606300715PR_NEWS_USPR_____NY94994) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.